Researchers at Stanford have developed orthoTeplizumab, an antibody that selectively recognizes engineered T cells without binding a patient's own T cells.
Researchers at Stanford have developed Electro-LEV, a microfluidic platform that uses programmable electromagnets to levitate and sort cells by their physical properties — with no fluorescent labels or antibodies required.
Stanford scientists have developed a cell-free method for producing high-purity plasmid DNA without the use of bacterial hosts. This approach eliminates contamination risks, reduces production time, and streamlines manufacturing for gene and cell therapies.
Stanford researchers have developed a modular system of Synthetic cytokine receptors (SCRs), which are customizable receptors that mimic cytokine signals to precisely control immune cell behavior without the need for external cytokines.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.